Maastricht, Netherlands: 3rd Meeting of the LYMIT-DIS consortium

The team members met on 19^th-20^th of September 2019 at the CARIM institute in Maastricht, Netherlands hosted by Partner 2 leader Dr Marc van Bilsen.

The Meeting was dedicated to presentation of results coupled with dynamic exchanges on the advancement of Project tasks and deliverables, with special focus on comparison of results between our different teams to further advance the work packages around investigations into HFpEF pathophysiology.

In beautiful Riga, Latvia, was held on 14^th to 16^th of May, 2019 the symposium of the Joint Transnational Calls JTC2016 ‘Heart Failure’, JTC2017 ‘Atherosclerosis’ and JTC2018 ‘Transnational Cardiovascular Research Projects driven by Early Career Scientists’.

Talks by our scientists at the Pint of Science festivals in Pamplona (ES), Leuven (BE) and Maastricht (NL)

Pamplona, Spain: 2^nd Meeting of the LYMIT-DIS consortium

The team members met on 19^th-21^st of September 2018 at the CIMA institute in Pamplona, Spain hosted by Partner 5 leader Dr Arantxa Gonzalez-Miqueo.

The Meeting was dedicated to intense & dynamic exchanges on the advancement of Project tasks and deliverables, with special focus on stimulating exchanges of methods and materials between our different teams to further advance the work packages.

ERA-NET on Cardio Vascular Diseases (ERA-CVD)

Cardiovascular diseases (CVD) are the major cause of death in Europe. CVD research is a crucial area in health research, hence an effective coordination of research at national and EU level, increased cross-disciplinary interaction and research advancements are needed. By gathering their forces and funding capacities so far 18 countries joined to set up a new ERA-Net Cofund action (European Research Area Network co-funded by the European Commission, EC) dedicated to cardiovascular diseases (ERA-CVD) .

Des chercheurs normands au chevet de cardiaques

Santé. À Rouen, un laboratoire a remporté un appel d’offres européen pour diriger un projet scientifique sur l’insuffisance cardiaque. Avec l’espoir de traiter la maladie.